^
Association details:
| Biomarker: | PIK3CA E542K |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | apitolisib (GDC-0980) (mTOR inhibitor, PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Excerpt:
Five PRs included SCCHN (n=3), clear cell ovarian (n=1), and adrenocortical tumor (n=1). One PR was confirmed for an E542K SCCHN PIK3CA mutant.
DOI:
10.1158/1078-0432.CCR-15-2225
Source:
Title:
The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer
Excerpt:
We further demonstrate that up-front combined inhibition with dasatinib and MEK1/2 or ERK1/2 inhibitors drives synergistic inhibition of growth and induction of apoptosis, indicating that combined inhibition may overcome mechanisms of survival in response to single-agent inhibition....Thus, we treated all four parental cell lines with increasing concentrations of dasatinib (0.019 – 1.25 μM) in combination with the MEK1/2 inhibitors, trametinib (0.001-0.1 μM) or selumetinib (0.05 - 0.8 μM), as well as the BCPAP and Cal62 cell lines with the ERK1/2 inhibitor, SCH772984 (0.005-0.5 μM...Additionally, combined Src and MEK1/2 inhibition also resulted in decreased clonogenic growth in both the BRAF- (BCPAP) and RAS- (Cal62) mutant cell lines in comparison to single agent treatments (Fig. S7A & B).
DOI:
10.1158/1535-7163.MCT-15-0702
